Dispelling Myths About CGM Coverage | Real-Time Real Talk by Dexcom™
January 11, 2023
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individualresults may vary – nothing you hear on this podcast should be considered medical advice. All claims are supportedby clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 UserGuide. For product-related questions, please refer to the instructions for use. For complete safety information, goto dexcom.com/safety-information.Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucosemonitoring device indicated for the management of diabetes in persons aged 2 years and older.Manisha Agarwal is a Dexcom employee and is a guest on this episode of the podcast.Dexcom G6 is covered for 3 out of 4 patients with T2D on mealtime insulin with commercial health insuranceplans.* Dexcom has three times more patients paying $0 than competing CGM systems 2 and is currently reimbursed bymore than 97% of private insurance 1 as well as Medicare nationwide and Medicaid in 45 states.CMS has proposed expanding Medicare coverage for CGMs to include people who are treated with insulin at leastonce per day or who have a history of problematic hypoglycemia. For more information, click here.About Hello DexcomDexcom Provider websiteDexcom G6 Prescribing InformationPatient Assistance ProgramPatient Coverage Evaluator (PaCE) A tool for prescriber offices to confirm patient’s pharmacy coverage anddetermine prescribing pathway.Data from collaborator devices and products must be verified by those collaborator devices and products. Usersshould confirm data and connections with their collaborator devices and products.Brief Safety StatementFailure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to theinstructions for use provided with your device and available at https://www.dexcom.com/safety-information andto properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions foruse may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose)occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings fromthe G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amountof 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals toassist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historicalCGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGMdevices with data interface capabilities. Caution: The software does not provide any medical advice and should notbe used for that purpose. Home users must consult a healthcare professional before making any medicalinterpretation and therapy adjustments from the information in the software. Caution: Healthcare professionalsshould use information in the software in conjunction with other clinical information available to them. Caution:Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S.,and may be registered in other countries.
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Manisha Agarwal is a Dexcom employee and is a guest on this episode of the podcast. Dexcom G6 is covered for 3 out of 4 patients with T2D on mealtime insulin with commercial health insurance plans.* Dexcom has three times more patients paying $0 than competing CGM systems 2 and is currently reimbursed by more than 97% of private insurance 1 as well as Medicare nationwide and Medicaid in 45 states. CMS has proposed expanding Medicare coverage for CGMs to include people who are treated with insulin at least once per day or who have a history of problematic hypoglycemia. For more information, click here. About Hello Dexcom Dexcom Provider website Dexcom G6 Prescribing Information Patient Assistance Program Patient Coverage Evaluator (PaCE) A tool for prescriber offices to confirm patient’s pharmacy coverage and determine prescribing pathway. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. Brief Safety Statement Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Manisha Agarwal is a Dexcom employee and is a guest on this episode of the podcast. Dexcom G6 is covered for 3 out of 4 patients with T2D on mealtime insulin with commercial health insurance plans.* Dexcom has three times more patients paying $0 than competing CGM systems 2 and is currently reimbursed by more than 97% of private insurance 1 as well as Medicare nationwide and Medicaid in 45 states. CMS has proposed expanding Medicare coverage for CGMs to include people who are treated with insulin at least once per day or who have a history of problematic hypoglycemia. For more information, click here. About Hello Dexcom Dexcom Provider website Dexcom G6 Prescribing Information Patient Assistance Program Patient Coverage Evaluator (PaCE) A tool for prescriber offices to confirm patient’s pharmacy coverage and determine prescribing pathway. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. Brief Safety Statement Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.